The European Commission (EC) has authorised the use of ViiV Healthcare’s Vocabria (cabotegravir long-acting injections) plus Rekambys (rilpivirine long-acting injections) from Johnson & Johnson (J&J) ...
The following is a summary of “Unconventional use of injectable long-acting cabotegravir and rilpivirine against HIV-1 in PWH ...
Cabotegravir and rilpivirine are medications used to treat HIV, delivered by injection. They have been engineered to stay in the body after injection for at least two months. In Europe, long-acting ...
Hosted on MSN1mon
GSK Gets CHMP Nod for Expanded Use of HIV Combo & JemperliThe CHMP recommended marketing authorization to Vocabria (cabotegravir long-acting injections) in combination with Johnson & Johnson’s JNJ Rekambys (rilpivirine long-acting injections ...
European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria plus Rekambys for HIV treatment in adolescents: London, UK Saturday, February 1, 2025, 11:00 Hrs ...
ViiV Healthcare has secured European Commission approval for its long-acting HIV treatment, Vocabria + Rekambys, for adolescents aged 12 and olde ...
London: GSK plc has announced that ViiV Healthcare, the global HIV company majority owned by GSK, with Pfizer and Shionogi as ...
GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has today announced that the European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback